Since CTLA-4 is expressed on DCs and has a significant effect on diminishing their function, we aimed to inhibit the expression of CTLA-4 in CRC cell lysate-pulsed-DCs via transfection of siRNA to enhance the efficacy of DC-based cancer immunotherapy. The gene discussed is CTLA4; the disease is colorectal carcinoma.